Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.68 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.64 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.64 |
| ▸ | PDE1A | P54750 | 3/20 | 0.56 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.56 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6332560 | 0.94 | PDE5A (0.62) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL6331817 | 0.91 | PDE5A (0.65) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL6339775 | 0.87 | PDE5A (0.61) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL6332520 | 0.87 | PDE5A (0.63) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL5596504 | 0.87 | PDE5A (0.80) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL6332848 | 0.86 | PDE5A (0.61) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL6340933 | 0.86 | PDE5A (0.58) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL6338901 | 0.85 | PDE5A (0.58) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL6332578 | 0.83 | PDE5A (0.68) | PDE5APDE3BPDE3A | |
| SCHEMBL1190 | 0.83 | PDE5A (0.90) | PDE5APDE3BPDE3APDE1APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6916927-B2 | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction | PFIZER INC. | 2005-07-12 | — | — | US | disclosed |
| US-20040180944-A1 | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction | PFIZER INC | 2004-09-16 | — | — | US | disclosed |
| US-6723719-B1 | DYSMENORRHOEA, BENIGN PROSTATIC HYPERPLASIA (BPH), BLADDER OUTLET OBSTRUCTION, INCONTINENCE, AGINA, CONGESTIVE HEART FAILURE, ATHEROSCLEROSIS; HYPOTENSIVE AND ANTIALLERGEN AGENTS | PFIZER INC | 2004-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180944-A1 | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction | PDE5A, PDE3A, PDE3B | PDE5A 1/4885PDE3B 3/4885PDE3A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.